Vivus Inc Revenue Growth Rates (VVUS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vivus Inc  (VVUS)
 

VVUS's Revenue Growth by Quarter and Year

Vivus Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VVUS Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 19.63
FY 19.63

VVUSs Annual Revenue
Vivus Inc's Revenue in the fiscal year 2019 $ 69.76 millions
Vivus Inc's Revenue in the fiscal year 2018 $ 65.06 millions
Vivus Inc's Revenue in the fiscal year 2017 $ 65.37 millions
Vivus Inc's Revenue in the fiscal year 2016 $ 124.26 millions
Vivus Inc's Revenue in the fiscal year 2015 $ 95.43 millions




VVUS Revenue first quarter 2020 Y/Y Growth Comment
Vivus Inc reported Revenue improvement of 21.55% year on year in the first quarter 2020, to $ 19.63 millions, this is lower than Vivus Inc's recent average Revenue surge of 2601.3%.

Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 93 other companies have achieved higher Revenue growth. While Vivus Inc' s Revenue rise of 21.55% ranks overall at the positon no. 975 in the first quarter 2020.


VVUS Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - -14.22 % 68.43 % -85.41 %
3rd Quarter September - -0.66 % 19.09 % 13.78 %
2nd Quarter June - 22.93 % 33.21 % -18.51 %
1st Quarter March 21.55 % 35.71 % -55.94 % 76.31 %
FY   - 7.22 % -0.47 % -

Financial Statements
Vivus Inc's first quarter 2020 Revenue $ 19.63 millions VVUS's Income Statement
Vivus Inc's first quarter 2019 Revenue $ 16.15 millions Quarterly VVUS's Income Statement


VVUS Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -4.01 % 11.17 % -21.4 %
3rd Quarter September - -2.28 % 20.92 % 35.26 %
2nd Quarter June - 13.87 % 25.71 % -58.42 %
1st Quarter March 13.8 % -19.69 % -0.34 % -66.98 %
FY (Year on Year)   - 7.22 % -0.47 % -


Back to VVUS Growth rate Comparisons >> Back to VVUS Growth rate Comparisons >>


Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #94
Healthcare Sector #208
Overall #975

Revenue Y/Y Growth Statistics
High Average Low
66678.05 % 2601.3 % -85.4 %
(Sep 30 2013)   (Dec 31 2015)
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #94
Healthcare Sector #208
Overall #975
Revenue Y/Y Growth Statistics
High Average Low
66678.05 % 2601.3 % -85.4 %
(Sep 30 2013)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Vivus Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4707.32 % 194.8 % -100 %
(Dec 31 2012)  


VVUS's I. Quarter Q/Q Revenue Comment
Vivus Inc achieved in the I. Quarter 2020 below company average Revenue rise of 13.8% quarter on quarter, to $ 19.63 millions.

Although the I. Quarter 2020 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the I. Quarter surge, eclipses the -19.69% growth in the I. Quarter a year ago

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Vivus Inc's Revenue growth quarter on quarter, overall rank is 878.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #193
Overall #878
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #193
Overall #878
Revenue Q/Q Growth Statistics
High Average Low
4707.32 % 194.8 % -100 %
(Dec 31 2012)  


VVUS's I. Quarter Q/Q Revenue Comment
Vivus Inc achieved in the I. Quarter 2020 below company average Revenue rise of 13.8% quarter on quarter, to $ 19.63 millions.

I. Quarter 2020 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -19.69% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Vivus Inc's Revenue growth quarter on quarter, overall rank is 878.


Vivus Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 73.25 $ 69.76 $ 72.62 $ 72.74 $ 69.31
Y / Y Revenue Growth (TTM) 5.68 % 7.22 % 27.65 % 34.71 % 37.9 %
Year on Year Revenue Growth Overall Ranking # 452 # 0 # 448 # 303 # 2199
Seqeuential Revenue Change (TTM) 5 % -3.94 % -0.16 % 4.95 % 6.53 %
Seq. Revenue Growth (TTM) Overall Ranking # 1765 # 3703 # 1136 # 593 # 3671


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2020 period, Vivus Inc's cumulative twelve months Revenue were $ 73 millions, company would post below average annual Revenue growth of 6.53% year on year, if the fiscal year would end at Mar 31 2020.
A slow-down in the Vivus Inc's Revenue growth from the 17.25% growth in Dec 31 2019.

In the Healthcare sector 119 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 452.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 117
Healthcare Sector # 120
Overall # 452

Revenue TTM Y/Y Growth Statistics
High Average Low
1015.18 %
 56.68 %
-63.03 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 117
Sector # 275
S&P 500 # 1765
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2020 period, Vivus Inc's cumulative twelve months Revenue were $ 73 millions, company would post below average annual Revenue growth of -63.03% year on year, if the fiscal year would end at Mar 31 2020.
A slow-down in the Vivus Inc's Revenue growth from the 17.25% growth in Dec 31 2019.

In the Healthcare sector 119 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 452.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 117
Healthcare Sector # 120
Overall # 452

Revenue TTM Y/Y Growth Statistics
High Average Low
1015.18 %
56.68 %
-63.03 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 117
Sector # 275
S&P 500 # 1765




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VVUS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Wave Life Sciences Ltd 37.51%$ 37.508 millions
Addus Homecare Corp36.60%$ 36.596 millions
Invo Fertility Inc 36.54%$ 36.536 millions
Personalis Inc 36.13%$ 36.135 millions
Irhythm Holdings Inc 34.57%$ 34.568 millions
10x Genomics Inc 34.21%$ 34.206 millions
Nuwellis Inc 34.16%$ 34.156 millions
Wearable Health Solutions, Inc.34.00%$ 33.997 millions
Accelerate Diagnostics Inc 33.83%$ 33.829 millions
Adm Tronics Unlimited Inc 33.77%$ 33.770 millions
Serina Therapeutics Inc 32.73%$ 32.732 millions
Viemed Healthcare Inc 31.42%$ 31.416 millions
Inspire Medical Systems inc 31.37%$ 31.366 millions
Novaccess Global Inc31.30%$ 31.300 millions
Sarepta Therapeutics Inc 30.64%$ 30.643 millions
Scorpius Holdings inc 28.64%$ 28.645 millions
Clovis Oncology inc 28.52%$ 28.522 millions
Precision Biosciences Inc28.12%$ 28.122 millions
Alector Inc 27.94%$ 27.939 millions
Quanterix Corporation27.48%$ 27.478 millions
Ptc Therapeutics inc 27.39%$ 27.389 millions
Koru Medical Systems Inc 27.25%$ 27.255 millions
Horizon Therapeutics Public Limited Company26.94%$ 26.942 millions
Stablecoin Development Corporation26.89%$ 26.895 millions
Alexion Pharmaceuticals Inc 26.69%$ 26.692 millions
Amneal Pharmaceuticals Inc 26.54%$ 26.540 millions
Schrodinger Inc 26.19%$ 26.194 millions
Clearpoint Neuro Inc 26.01%$ 26.009 millions
Sorrento Therapeutics Inc 25.69%$ 25.688 millions
Repligen Corp25.49%$ 25.491 millions


About Vivus Inc Revenue Growth Rates (VVUS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.